The risk for significant creatine kinase elevation with statins.

Area of Science:

• Cardiology
• Pharmacology
• Clinical Research

Background:

• Statins (HMG-CoA reductase inhibitors) are vital for cardiovascular disease prevention.
• Rhabdomyolysis, a severe adverse effect of statins, involves significant creatine kinase (CK) elevation.
• Real-world data on statin-associated rhabdomyolysis risk is limited.

Purpose of the Study:

• To investigate the risk of CK elevation in patients using statins within a clinical practice setting.
• To identify and evaluate potential risk factors associated with statin-induced CK elevation.

Main Methods:

• A case-control study involving patients prescribed lovastatin or simvastatin.
• Cases (n=183) had CK > or =10x ULN; controls (n=1830) did not, matched by statin purchase date.
• Multivariate conditional logistic regression analyzed associations between statins, dose, demographics, comorbidities, and medications.

Main Results:

• Simvastatin use showed a higher likelihood of CK elevation (> or =10x ULN) than lovastatin (aOR 4.6).
• High-dose simvastatin (80 mg) increased risk (aOR 2.7) compared to simvastatin 40 mg, particularly with interacting medications.
• Lovastatin 80 mg also showed increased risk when used with interacting medications.

Conclusions:

• Simvastatin is associated with a greater risk of significant CK elevation than lovastatin.
• High-dose simvastatin poses a higher risk for CK elevation compared to lower doses of either statin.
• These findings highlight the importance of dose and drug interactions in statin-associated myopathy.